doi: 10.1021/jm301296t.
Epub 2012 Nov 21.
Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687)
Affiliations
- PMID: 23116186
- DOI: 10.1021/jm301296t
Item in Clipboard
Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687)
J Med Chem.
.
Abstract
A new series of pyrazinecarboxamide DGAT1 inhibitors was designed to address the need for a candidate drug with good potency, selectivity, and physical and DMPK properties combined with a low predicted dose in man. Rational design and optimization of this series led to the discovery of compound 30 (AZD7687), which met the project objectives for potency, selectivity, in particular over ACAT1, solubility, and preclinical PK profiles. This compound showed the anticipated excellent pharmacokinetic properties in human volunteers.
Similar articles
-
Evolving data analysis of an Oral Lipid Tolerance Test toward the standard for the Oral Glucose Tolerance Test: Cross species modeling effects of AZD7687 on plasma triacylglycerol.Pharmacol Res Perspect. 2019 Mar 9;7(2):e00465. doi: 10.1002/prp2.465. eCollection 2019 Apr. Pharmacol Res Perspect. 2019. PMID: 30899516 Free PMC article.
-
Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study.Diabetes Obes Metab. 2013 Feb;15(2):136-43. doi: 10.1111/dom.12002. Epub 2012 Sep 30. Diabetes Obes Metab. 2013. PMID: 22950654 Clinical Trial.
-
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial.Diabetes Obes Metab. 2014 Apr;16(4):334-43. doi: 10.1111/dom.12221. Epub 2013 Oct 31. Diabetes Obes Metab. 2014. PMID: 24118885 Clinical Trial.
-
Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors.J Med Chem. 2013 Dec 27;56(24):9820-5. doi: 10.1021/jm4007033. Epub 2013 Sep 3. J Med Chem. 2013. PMID: 23919406 Review.
-
DGAT1 inhibitors as anti-obesity and anti-diabetic agents.Curr Opin Drug Discov Devel. 2010 Jul;13(4):489-96. Curr Opin Drug Discov Devel. 2010. PMID: 20597032 Review.
Cited by
-
Evolving data analysis of an Oral Lipid Tolerance Test toward the standard for the Oral Glucose Tolerance Test: Cross species modeling effects of AZD7687 on plasma triacylglycerol.Pharmacol Res Perspect. 2019 Mar 9;7(2):e00465. doi: 10.1002/prp2.465. eCollection 2019 Apr. Pharmacol Res Perspect. 2019. PMID: 30899516 Free PMC article.
-
UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.J Med Chem. 2014 Aug 28;57(16):7031-41. doi: 10.1021/jm500749d. Epub 2014 Aug 6. J Med Chem. 2014. PMID: 25068800 Free PMC article.
-
The Reactivity of Azidonitrobenzofuroxans towards 1,3-Dicarbonyl Compounds: Unexpected Formation of Amino Derivative via the Regitz Diazo Transfer and Tautomerism Study.Int J Mol Sci. 2021 Sep 6;22(17):9646. doi: 10.3390/ijms22179646. Int J Mol Sci. 2021. PMID: 34502553 Free PMC article.
-
Reprogramming of lipid metabolism in the tumor microenvironment: a strategy for tumor immunotherapy.Lipids Health Dis. 2024 Feb 1;23(1):35. doi: 10.1186/s12944-024-02024-0. Lipids Health Dis. 2024. PMID: 38302980 Free PMC article. Review.
-
Discovery of a Potent and Selective DGAT1 Inhibitor with a Piperidinyl-oxy-cyclohexanecarboxylic Acid Moiety.ACS Med Chem Lett. 2014 Sep 8;5(10):1082-7. doi: 10.1021/ml5003426. eCollection 2014 Oct 9. ACS Med Chem Lett. 2014. PMID: 25349648 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases
Miscellaneous
